Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
University of Rochester NCORP Research Base
Status
Recruiting
NCT ID
NCT03996265
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Intervention
Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Condition
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Investigators
Heather S Jim, William J. Irvin, Bryan A. Faller, Ki Y. Chung, Elie G. Dib, Gregory A. Masters, Alison K. Conlin, John A. Ellerton, Jay W. Carlson, Samantha A. Seaward, Alexander Menter, Jami A. Fukui, Maria T. Grosse-Perdekamp, Howard M. Gross, Vinay K. Gudena, Bolanle Gbadamosi, Namita Sharma, Amarinthia (Amy) Curtis, Ana M. Ventura, Matthias Weiss, Kamal Kant Singh Abbi, Brian L. Burnette, Chady A. Leon, Site Public Contact, Andrew J. Huang, William A. Wilson, Suma P. Satti, Sarah E. Gill, Kathleen Y. Butler, Matthew Rendo, Bharat Jenigiri, Nicholas J. DiBella, Augusto C. Ochoa, Heather D. Zinkin, Gena H. Volas-Redd, Antonio J. Ruiz, Jeffrey L. Berenberg, Sarah E. Jax
CT Research Area
Symptom Science